Statement by the Prime Minister for Mental Health Week
OTTAWA, May 6, 2019 /CNW/ - The Prime Minister, Justin Trudeau, today issued the following statement for Mental Health Week:
"This week, let's all speak up and raise our voices for mental health. Mental Health Week, led by the Canadian Mental Health Association, encourages everyone to talk freely about what mental health means to us and listen compassionately to the stories of others.
"Mental health affects all of us. Yet too often, this important part of our wellbeing is dismissed or stigmatized, leaving people to suffer in silence. By being open and talking about mental health with others, we can break down the stigma and make sure everyone gets the support they need.
"The Government of Canada is working with provinces, territories, Indigenous communities, and other partners to improve access to mental health services. Past budgets have reinforced this commitment, and helped provide people across the country with the mental health care they need. By working together, we can help make sure all Canadians have access to these vital health care services.
"We've all been affected by mental health, whether we know someone who has experienced a mental health issue or whether we've gone through these struggles ourselves. There is no shame in struggling with a mental health issue. Today and every day, let's work to end stigma and make sure everyone has the support they need."
The 31st Canadian Cancer Society (CCS) Daffodil Ball, which took place this evening at Windsor Station in Montreal, raised $1,474,785 to fund innovative research projects and essential support programs for people living with cancer. The largest...
The report titled "Clinical Trials Matching Software Market by Functionality (Analytics & Reporting, Compliance Tracking, Data Management), Deployment (Cloud & Web Based, On-Premise), End-Use - Global Forecast 2024-2030" is now available on...
South Korea's biotechnology company Hyundai Bioscience (CEO Oh Sang-gi, www.hyundaibioscience.com) announced on April 15 that it would carry out global clinical tests aimed at treating all serotypes of Dengue virus infection....
RevolKa Ltd. (Norio Hamamatsu, President & CEO), a venture-backed biotech company providing a game-changing protein engineering technology platform and La Jolla Institute for Immunology (LJI) (Erica Saphire, President & CEO) agreed to start a...
Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved ENTYVIO® (vedolizumab) subcutaneous (SC) administration for maintenance therapy in adults with moderately to severely active Crohn's disease (CD)...